The use of eponyms in neurology reached its peak at the end of the 19 th century and the beginning of the 20 st1 to the point that many diseases are known worldwide by their eponyms, such as Alzheimer's disease, Parkinson's disease and Wilson's disease 1, 2 . However, in the last decades of the 20 th century, the use of eponyms for neurological diseases increasingly gave way to the use of more scientific names and acronyms, such as restless legs syndrome (RLS), acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and amyotrophic lateral sclerosis (ALS). Curiously, in recent years the situation has changed dramatically and certain eponyms have been abandoned for a variety of reasons while others have been kept or even changed, not without a certain amount of surrounding controversy 1, 2 . The present review addresses this issue and how it impacts in the current branding of RLS, ALS, neurodegeneration with brain iron accumulation (NBIA) and Guillain-Barré syndrome (GBS).
Restless legs syndRome/Willis-ekbom disease RLS was first described in 1685 by Sir Thomas Willis, but other researchers, including Huss and Wittmaack, have since made significant contributions to the study of this disease 3 . However, the most significant contribution was the description by professor Karl Ekbom, who published two classic articles in 1944 and 1945, most notably the latter 3 . After various studies on RLS were published by Ekbom, the disease became known around the world as Ekbom's syndrome 3 , but at the end of the last century, this eponym fell into increasing disuse and the term RLS was commonly used 3 . In 2013, the International Restless Legs Syndrome Study Group suggested that the name of the disease should be changed to an amalgamated form, RLS/Willis-Ekbom disease, as a tribute to the first person to ever study it (Thomas Willis) and the first detailed clinical description of the disease by Karl Ekbom 4 . Accordingly, in 2014 the revised diagnostic criteria for Restless legs syndrome/Willis-Ekbom disease were published 4 .
neuRodegeneRation With bRain iRon aCCumulation
Neurodegeneration with brain iron accumulation (NBIA) represents a heterogeneous group of inherited neurodegenerative diseases characterized by excess iron accumulation, particularly in the basal ganglia and to a lesser degree in the substantia nigra and adjacent regions 5 . Common clinical features of NBIA include movement disorders, particularly parkinsonism and dystonia, cognitive dysfunction, pyramidal signs and retinal abnormalities 5 . In 1922, Hallervorden and Spatz reported the case of a family with five affected sisters with dystonia, cognitive dysfunction and confirmed neuropathological lesions of the globus pallidus and substantia nigra 5, 6 . After this kindred-case description, the disease became known around the world as Hallervorden-Spatz syndrome (HSS) 5, 6 . But, in spite of their seminal description, a shadowy past would lead to a change in nomenclature for this syndrome: Julius Hallervorden and Hugo Spatz were important German neuropathologists who performed several neuropathological studies on brain specimens of individuals with mental retardation executed during the Third Reich euthanasia program 5, 6 . After confirmation of Hallervorden's and Spatz's involvement in the euthanasia program operated by the Nazi regime in Germany and recent neuroimaging and genetic discoveries, this syndrome was renamed NBIA 5, 6 . To date, ten forms of NBIA have been described, the most common of which are pantothenate kinase-associated neurodegeneration (PKAN), caused by mutations in the PANK2 gene 5 .
guillain-baRRé syndRome
Guillain-Barré syndrome (GBS) was first described in 1916 by George Guillain, Jean-Alexandre Barré and André Strohl . The disease is a form of acute autoimmune polyradiculoneuropathy. A characteristic finding is albuminocytological dissociation in the cerebrospinal fluid, and the clinical presentation is typically an ascending flaccid paralysis with loss of deep tendon reflexes 7 . The eponym GBS has been the subject of continual discussion since the early 20 th century and different opinions and suggestions have been put forward regarding alternative eponyms. Some authors suggest that the eponym Guillain-Barré-Strohl should be used because of André Strohl' s important contribution to the electrophysiology studies required to investigate this condition 7 , while others suggest that the name of Octave Landry, who described the syndrome as "acute ascending paralysis" in 1859, should be included in the eponym. In 1876, the disease became known as "Landry (ascending) paralysis", and after 1956 it was known as "Landry-Guillain-Barré syndrome" or even "Landry-Guillain-Barré-Strohl syndrome" 7, 8 . Other authors proposed the name "Wardrop-Guillain-Barré-Landry-Strohl" because of the description of cases of rapidly progressive paralysis and other features of GBS by James Wardrop and Charles-Prosper Ollivier
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. Currently, the traditional form GBS is the most widely used eponym, together with the descriptive names acute inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyradiculoneuropathy.
amyotRoPhiC lateRal sCleRosis (als)
ALS is a fatal neurodegenerative disease first described in the 19th century by Salpêtrière school's most famous professor, Jean-Martin Charcot, considered the father of neurology 9 . Charcot described the disease in 1874 after reporting various forms of the condition in detail and called it amyotrophic lateral sclerosis 9, 10 . This was undoubtedly one of Charcot's greatest contributions to neurology. Ever since the disease has become known as Charcot's disease, particularly in Europe. However, in some places, especially the USA, the condition is known as Lou Gehrig's disease, in memory of the famous American baseball player who died 74 years ago and allegedly suffered from the condition 9 . While this is a popular eponym for ALS in the USA, Charcot's contribution to the definition of the disease remains paramount and, above all, the eponym "Charcot's disease" must not be forgotten.
Final RemaRks
The use of eponyms in Neurology remains controversial to this day and a matter of much debate. What can be observed in recent years is that the factors governing whether certain neurologic eponyms are used, changed or excluded vary widely, often due to political factors. For example, despite Hallervorden's and Spatz's original scientific contribution, the eponym Hallervorden-Spatz syndrome was replaced by NBIA because of their past as Nazi criminals. Another eponym, Charcot's disease, has been forgotten or replaced by ALS, or Lou Gehrig's disease. The eponym GBS is still the subject of controversy, and various names have been suggested that could be used in variations of the classical form. Finally, RLS, which for several years had been known as Ekbom's syndrome and then RLS, was recently defined as an amalgamated form -RLS/Willis-Ekbom syndrome 4, 6, 7, 9 .
